^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAC01-CD19

    i
    Other names: TAC01-CD19, CD19 TAC, CD19-TAC01, TAC-921
    Associations

    News

    Trials
    Company:
    Triumvira
    Drug class:
    CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Triumvira Immunologics, Inc. | N=36 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    TAC01-CD19
    4years
    TACTIC-19: Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, Triumvira Immunologics, Inc. | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2021 --> Apr 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    TAC01-CD19